25.99 USD
-0.54 (-2.04%)
25.99 USD
0 (0%)
Overall ACAD gets a fundamental rating of 5 out of 10. We evaluated ACAD against 525 industry peers in the Biotechnology industry. While ACAD has a great health rating, its profitability is only average at the moment. ACAD is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year ACAD was profitable.
- ACAD had a positive operating cash flow in the past year.
- ACAD had negative earnings in each of the past 5 years.
- In the past 5 years ACAD always reported negative operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of 19.63%, ACAD belongs to the best of the industry, outperforming 96.95% of the companies in the same industry.
- ACAD's Return On Equity of 28.47% is amongst the best of the industry. ACAD outperforms 97.52% of its industry peers.
- ACAD has a better Return On Invested Capital (7.66%) than 93.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROIC | 7.66% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ACAD's Profit Margin of 24.94% is amongst the best of the industry. ACAD outperforms 95.05% of its industry peers.
- With an excellent Operating Margin value of 9.02%, ACAD belongs to the best of the industry, outperforming 91.24% of the companies in the same industry.
- The Gross Margin of ACAD (91.92%) is better than 93.33% of its industry peers.
- In the last couple of years the Gross Margin of ACAD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ACAD is destroying value.
- Compared to 1 year ago, ACAD has more shares outstanding
- ACAD has more shares outstanding than it did 5 years ago.
- There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 5.85 indicates that ACAD is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.85, ACAD is in the better half of the industry, outperforming 75.24% of the companies in the same industry.
- There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 5.85 |
ROIC/WACC0.86
WACC8.88%
2.3 Liquidity
- A Current Ratio of 3.02 indicates that ACAD has no problem at all paying its short term obligations.
- ACAD's Current ratio of 3.02 is on the low side compared to the rest of the industry. ACAD is outperformed by 63.81% of its industry peers.
- A Quick Ratio of 2.94 indicates that ACAD has no problem at all paying its short term obligations.
- The Quick ratio of ACAD (2.94) is worse than 62.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 |
3. Growth
3.1 Past
- ACAD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.10%.
- ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 121.75%.
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
3.2 Future
- ACAD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.40% yearly.
- ACAD is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.47% yearly.
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue Next Year11.07%
Revenue Next 2Y11.43%
Revenue Next 3Y11.21%
Revenue Next 5Y10.47%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 38.79, the valuation of ACAD can be described as expensive.
- ACAD's Price/Earnings ratio is rather cheap when compared to the industry. ACAD is cheaper than 91.43% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 27.38. ACAD is valued slightly more expensive when compared to this.
- Based on the Price/Forward Earnings ratio of 32.28, the valuation of ACAD can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 91.81% of the companies listed in the same industry.
- ACAD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 24.29.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.79 | ||
| Fwd PE | 32.28 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 92.95% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, ACAD is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.2 | ||
| EV/EBITDA | 27.3 |
4.3 Compensation for Growth
- ACAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of ACAD may justify a higher PE ratio.
- A more expensive valuation may be justified as ACAD's earnings are expected to grow with 35.28% in the coming years.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y29.52%
EPS Next 3Y35.28%
5. Dividend
5.1 Amount
- No dividends for ACAD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
25.99
-0.54 (-2.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners101.21%
Inst Owner Change0.05%
Ins Owners0.26%
Ins Owner Change-3.63%
Market Cap4.40B
Revenue(TTM)1.05B
Net Income(TTM)261.17M
Analysts76.92
Price Target30.87 (18.78%)
Short Float %5.18%
Short Ratio5.57
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)96.34%
Min EPS beat(2)14.46%
Max EPS beat(2)178.22%
EPS beat(4)2
Avg EPS beat(4)20.1%
Min EPS beat(4)-109.07%
Max EPS beat(4)178.22%
EPS beat(8)5
Avg EPS beat(8)29%
EPS beat(12)7
Avg EPS beat(12)26.97%
EPS beat(16)10
Avg EPS beat(16)24.21%
Revenue beat(2)0
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-1.19%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-2.59%
Min Revenue beat(4)-8.33%
Max Revenue beat(4)0.08%
Revenue beat(8)3
Avg Revenue beat(8)-1.62%
Revenue beat(12)5
Avg Revenue beat(12)-0.37%
Revenue beat(16)6
Avg Revenue beat(16)-1.45%
PT rev (1m)3.42%
PT rev (3m)4.16%
EPS NQ rev (1m)2.09%
EPS NQ rev (3m)8.32%
EPS NY rev (1m)-1.14%
EPS NY rev (3m)43.73%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)2.41%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.01%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 38.79 | ||
| Fwd PE | 32.28 | ||
| P/S | 4.2 | ||
| P/FCF | 20.2 | ||
| P/OCF | 13.84 | ||
| P/B | 4.79 | ||
| P/tB | 5.46 | ||
| EV/EBITDA | 27.3 |
EPS(TTM)0.67
EY2.58%
EPS(NY)0.81
Fwd EY3.1%
FCF(TTM)1.29
FCFY4.95%
OCF(TTM)1.88
OCFY7.23%
SpS6.19
BVpS5.42
TBVpS4.76
PEG (NY)0.54
PEG (5Y)N/A
Graham Number9.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.63% | ||
| ROE | 28.47% | ||
| ROCE | 9.69% | ||
| ROIC | 7.66% | ||
| ROICexc | 58.65% | ||
| ROICexgc | 479.54% | ||
| OM | 9.02% | ||
| PM (TTM) | 24.94% | ||
| GM | 91.92% | ||
| FCFM | 20.79% |
ROA(3y)-13.43%
ROA(5y)-20.05%
ROE(3y)-13.54%
ROE(5y)-23.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.57%
GM growth 5Y2.57%
F-Score4
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 711.57% | ||
| Cap/Sales | 9.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 292.92% | ||
| Profit Quality | 83.36% | ||
| Current Ratio | 3.02 | ||
| Quick Ratio | 2.94 | ||
| Altman-Z | 5.85 |
F-Score4
WACC8.88%
ROIC/WACC0.86
Cap/Depr(3y)241.55%
Cap/Depr(5y)203.25%
Cap/Sales(3y)567.7%
Cap/Sales(5y)341.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%110%
EPS Next Y71.6%
EPS Next 2Y29.52%
EPS Next 3Y35.28%
EPS Next 5Y39.4%
Revenue 1Y (TTM)121.75%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.27%
Revenue Next Year11.07%
Revenue Next 2Y11.43%
Revenue Next 3Y11.21%
Revenue Next 5Y10.47%
EBIT growth 1Y50.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.82%
EBIT Next 3Y27.27%
EBIT Next 5Y43.9%
FCF growth 1Y264.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y443.26%
OCF growth 3YN/A
OCF growth 5YN/A
ACADIA PHARMACEUTICALS INC / ACAD FAQ
What is the fundamental rating for ACAD stock?
ChartMill assigns a fundamental rating of 5 / 10 to ACAD.
What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?
ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.
Can you provide the profitability details for ACADIA PHARMACEUTICALS INC?
ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.
What are the PE and PB ratios of ACADIA PHARMACEUTICALS INC (ACAD) stock?
The Price/Earnings (PE) ratio for ACADIA PHARMACEUTICALS INC (ACAD) is 38.79 and the Price/Book (PB) ratio is 4.79.
Can you provide the financial health for ACAD stock?
The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 7 / 10.